Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy. [electronic resource]
Producer: 20161103Description: 4770-84 p. digitalISSN:- 1949-2553
- Adult
- Aged
- Aged, 80 and over
- Anthracyclines -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- metabolism
- Bone Morphogenetic Protein Receptors, Type I -- metabolism
- Breast Neoplasms -- drug therapy
- Bridged-Ring Compounds -- administration & dosage
- Carcinoma, Ductal, Breast -- drug therapy
- Female
- Follow-Up Studies
- Humans
- Immunoenzyme Techniques
- Lymphatic Metastasis
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Grading
- Neoplasm Invasiveness
- Neoplasm Staging
- Prognosis
- Receptor, ErbB-2 -- metabolism
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Retrospective Studies
- Survival Rate
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.